| Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota M Vétizou, JM Pitt, R Daillère, P Lepage, N Waldschmitt, C Flament, ... Science 350 (6264), 1079-1084, 2015 | 3385 | 2015 |
| Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients D Davar, AK Dzutsev, JA McCulloch, RR Rodrigues, JM Chauvin, ... Science 371 (6529), 595-602, 2021 | 1168 | 2021 |
| Resistance mechanisms to immune-checkpoint blockade in cancer: tumor-intrinsic and-extrinsic factors JM Pitt, M Vétizou, R Daillère, MP Roberti, T Yamazaki, B Routy, ... Immunity 44 (6), 1255-1269, 2016 | 1021 | 2016 |
| Enterococcus hirae and Barnesiella intestinihominis facilitate cyclophosphamide-induced therapeutic immunomodulatory effects R Daillère, M Vétizou, N Waldschmitt, T Yamazaki, C Isnard, ... Immunity 45 (4), 931-943, 2016 | 840 | 2016 |
| Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response CN Spencer, JL McQuade, V Gopalakrishnan, JA McCulloch, M Vetizou, ... Science 374 (6575), 1632-1640, 2021 | 573 | 2021 |
| Cancer and the gut microbiota: an unexpected link L Zitvogel, L Galluzzi, S Viaud, M Vétizou, R Daillère, M Merad, ... Science translational medicine 7 (271), 271ps1-271ps1, 2015 | 516 | 2015 |
| Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1 JA McCulloch, D Davar, RR Rodrigues, JH Badger, JR Fang, AM Cole, ... Nature medicine 28 (3), 545-556, 2022 | 279 | 2022 |
| MHC class II antigen presentation by the intestinal epithelium initiates graft-versus-host disease and is influenced by the microbiota M Koyama, P Mukhopadhyay, IS Schuster, AS Henden, J Hülsdünker, ... Immunity 51 (5), 885-898. e7, 2019 | 224 | 2019 |
| Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade N Jacquelot, T Yamazaki, MP Roberti, CPM Duong, MC Andrews, ... Cell research 29 (10), 846-861, 2019 | 223 | 2019 |
| Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25 D Hannani, M Vetizou, D Enot, S Rusakiewicz, N Chaput, D Klatzmann, ... Cell research 25 (2), 208-224, 2015 | 204 | 2015 |
| Fine-tuning cancer immunotherapy: optimizing the gut microbiome JM Pitt, M Vétizou, N Waldschmitt, G Kroemer, M Chamaillard, IG Boneca, ... Cancer research 76 (16), 4602-4607, 2016 | 123 | 2016 |
| The oncolytic peptide LTX-315 overcomes resistance of cancers to immunotherapy with CTLA4 checkpoint blockade T Yamazaki, JM Pitt, M Vétizou, A Marabelle, C Flores, Ø Rekdal, ... Cell Death & Differentiation 23 (6), 1004-1015, 2016 | 77 | 2016 |
| Chemokine receptor patterns in lymphocytes mirror metastatic spreading in melanoma N Jacquelot, DP Enot, C Flament, N Vimond, C Blattner, JM Pitt, ... The Journal of clinical investigation 126 (3), 921-937, 2016 | 76 | 2016 |
| Enhancing the clinical coverage and anticancer efficacy of immune checkpoint blockade through manipulation of the gut microbiota JM Pitt, M Vétizou, I Gomperts Boneca, P Lepage, M Chamaillard, ... Oncoimmunology 6 (1), e1132137, 2017 | 62 | 2017 |
| Cell-death-associated molecular patterns as determinants of cancer immunogenicity S Ladoire, D Hannani, M Vetizou, C Locher, L Aymeric, L Apetoh, O Kepp, ... Antioxidants & redox signaling 20 (7), 1098-1116, 2014 | 58 | 2014 |
| Antitumor immunity induced by antibody-based natural killer cell engager therapeutics armed with not-alpha IL-2 variant O Demaria, L Gauthier, M Vetizou, AB Alvarez, C Vagne, G Habif, ... Cell Reports Medicine 3 (10), 2022 | 49 | 2022 |
| Contribution of humoral immune responses to the antitumor effects mediated by anthracyclines D Hannani, C Locher, T Yamazaki, V Colin-Minard, M Vetizou, L Aymeric, ... Cell Death & Differentiation 21 (1), 50-58, 2014 | 38 | 2014 |
| Anti-PD1 in the wonder-gut-land M Vetizou, G Trinchieri Cell Research 28 (3), 263-264, 2018 | 36 | 2018 |
| Microbiome as an immunological modifier M Kumar, P Singh, S Murugesan, M Vetizou, J McCulloch, JH Badger, ... Biomarkers for immunotherapy of cancer: Methods and protocols, 595-638, 2020 | 33 | 2020 |
| Fas ligand deficiency impairs tumor immunity by promoting an accumulation of monocytic myeloid-derived suppressor cells S Peyvandi, S Buart, B Samah, M Vétizou, Y Zhang, L Durrieu, M Polrot, ... Cancer Research 75 (20), 4292-4301, 2015 | 33 | 2015 |